National Center for Advancing Translational Sciences; Notice of Closed Meeting, 72610 [2021-27689]
Download as PDF
<![CDATA[
72610
Federal Register / Vol. 86, No. 243 / Wednesday, December 22, 2021 / Notices
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability. ICCVAM also
promotes the scientific validation and
regulatory acceptance of testing
methods that more accurately assess the
safety and hazards of chemicals and
products and replace, reduce, or refine
animal use.
The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) establishes
ICCVAM as a permanent interagency
committee of the National Institute of
Environmental Health Sciences and
provides the authority for ICCVAM
involvement in activities relevant to the
development of alternative test
methods. Additional information about
ICCVAM can be found at https://
ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM,
provides support for ICCVAM-related
activities, and conducts and publishes
analyses and evaluations of data from
new, revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative test methods
and strategies for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
Dated: December 16, 2021.
Brian R. Berridge,
Associate Director, National Toxicology
Program.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
Jkt 256001
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; National Center for
Advancing Translational Sciences Special
Emphasis Panel.
Date: February 23, 2022.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carol (Chang-Sook) Kim,
Ph.D., Scientific Review Administrator,
Office of Grants Management and Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (301) 827–7940,
carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Name of Committee: National Advisory
Neurological Disorders and Stroke Council.
Date: February 2–3, 2022.
Open: February 2, 2022, 1:00 p.m. to 6:00
p.m.
Agenda: Report by the Director, NINDS;
Report by the Director, Division of
Extramural Activities; and Administrative
and Program Developments.
Open session will be videocast from this
link: https://videocast.nih.gov/.
Closed: February 3, 2022, 1:00 p.m. to 5:30
p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive Blvd.,
Rockville, MD 20852 (Virtual Meeting).
Contact Person: Robert Finkelstein, Ph.D.,
Director of Extramural Research, National
Institute of Neurological Disorders and
Stroke, NIH, 6001 Executive Blvd., Suite
3309, MSC 9531, Rockville, MD 20852, (301)
496–9248, finkelsr@ninds.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice at least 10 days in advance of the
meeting. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
www.ninds.nih.gov, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: December 16, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–27689 Filed 12–21–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Neurological
Disorders and Stroke Notice of
Meeting
BILLING CODE 4140–01–P
17:55 Dec 21, 2021
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institutes of Health
[FR Doc. 2021–27692 Filed 12–21–21; 8:45 am]
VerDate Sep<11>2014
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Neurological Disorders and Stroke
Council.
The meeting will be open to the
public. Individuals who plan to
participate and need special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify the Contact Person listed
below in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Dated: December 16, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–27724 Filed 12–21–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Automated Commercial Environment
(ACE) Export Manifest for Air Cargo
Test: Extension of Test
U.S. Customs and Border
Protection; Department of Homeland
Security.
ACTION: General notice.
AGENCY:
This notice announces that
U.S. Customs and Border Protection
SUMMARY:
E:\FR\FM\22DEN1.SGM
22DEN1
]]>Agencies
[Federal Register Volume 86, Number 243 (Wednesday, December 22, 2021)]
[Notices]
[Page 72610]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-27689]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; National Center for Advancing
Translational Sciences Special Emphasis Panel.
Date: February 23, 2022.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Center for Advancing Translational Sciences,
National Institutes of Health, 6701 Democracy Boulevard, Room 1037,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carol (Chang-Sook) Kim, Ph.D., Scientific Review
Administrator, Office of Grants Management and Scientific Review,
National Center for Advancing Translational Sciences, National
Institutes of Health, 6701 Democracy Boulevard, Room 1037, Bethesda,
MD 20892 (301) 827-7940, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B--Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Dated: December 16, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-27689 Filed 12-21-21; 8:45 am]
BILLING CODE 4140-01-P
